{"category":{"kind":"industry","slug":"biotech","name":"BioTech","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-02T12:02:47.147Z","updated_at":"2026-09-02T12:02:47.147Z","example":false,"profile_url":"/industries/biotech","is_stub":true,"member_count":170,"member_counts":{"accelerator":11,"company":159}},"members":[{"listing_type":"company","name":"ImpriMed","slug":"imprimed","tagline":"AI-driven precision medicine for oncology, veterinary, and pharma CRO","description":"ImpriMed is an AI precision-medicine company that predicts patient-specific drug responses for oncology. It began in veterinary cancer care (canine and feline blood cancers) and also serves human oncology and pharmaceutical CRO use cases with live-cell drug-response testing and precision analytics. Public site: imprimedicine.com.","url":"https://www.imprimedicine.com/","is_stealth":false,"normalized_domain":"imprimedicine.com","normalized_url_key":"imprimedicine.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/61424e4c194b4329bd3c0096/6a7fb90095ffed595d081960_ImpriMed_Logo_dark.png","links":[{"label":"X / Twitter","url":"https://x.com/imprimedicine","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/imprimed-inc","platform":"linkedin"},{"label":"YouTube","url":"https://www.youtube.com/channel/UCC6uyRplSyJcFWE0NldiF4Q","platform":"youtube"},{"label":"Instagram","url":"https://www.instagram.com/imprimedicine","platform":"instagram"},{"label":"Facebook","url":"https://www.facebook.com/imprimedicine","platform":"facebook"}],"entry_points":[{"kind":"homepage","url":"https://www.imprimedicine.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.imprimedicine.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2f338f37-f051-40b9-bdf1-ff76d7555985"},"categories":["Biotech","Healthcare","AI","Drug Discovery"],"stage":"series-a","founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/imprimedicine","github":null,"linkedin":"https://www.linkedin.com/company/imprimed-inc","contact_email":null,"added_at":"2026-09-20T17:07:23.828Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T17:07:23.828Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-20T17:07:23.828Z","updated_at":"2026-09-20T17:07:23.828Z"}},{"listing_type":"company","name":"Cellino","slug":"cellino","tagline":"AI-guided biomanufacturing for personalized regenerative medicine","description":"Cellino builds autonomous manufacturing systems for personalized regenerative medicine. Its technology stack combines deep learning, laser cell management, and closed-loop optical bioprocesses to produce patient-specific cells and tissues, aiming to make autologous iPSC-derived therapies more reproducible and scalable. The company partners with tissue-engineering firms such as Polyphron and publishes at cellinobio.com.","url":"https://cellinobio.com/","is_stealth":false,"normalized_domain":"cellinobio.com","normalized_url_key":"cellinobio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cellinobio.com/apple-touch-icon.png","links":[{"label":"X / Twitter","url":"https://x.com/CellinoBio","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/cellinobio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://cellinobio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://cellinobio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"b4d05a07-026e-44bd-85f9-ba3291fe6194"},"categories":["Biotech","Healthcare","AI","Manufacturing"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/CellinoBio","github":null,"linkedin":"https://www.linkedin.com/company/cellinobio","contact_email":null,"added_at":"2026-09-20T17:07:08.206Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T17:07:08.206Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"manufacturing","name":"Manufacturing","note":null,"profile_url":"/industries/manufacturing"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-20T17:07:08.206Z","updated_at":"2026-09-20T17:07:08.206Z"}},{"listing_type":"company","name":"Anew Labs","slug":"anew-labs","tagline":"AI drug discovery combining models with experimental science","description":"Anew Labs (also referred to as Anew Therapeutics) is an AI pharmaceutical company applying machine learning to drug discovery. Its public platform work spans structure prediction, dynamics-aware sampling, all-atom generative modeling, antibody design, and scientific reasoning models, combined with experimental science and drug-discovery expertise. The company lists offices in Shanghai, San Francisco, and Singapore.","url":"https://anewbt.com/","is_stealth":false,"normalized_domain":"anewbt.com","normalized_url_key":"anewbt.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://anewbt.com/assets/anew-logo-en-long.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/anew-labs","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://anewbt.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://anewbt.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"e9817002-ecc6-4b97-ba5b-ec6d37f12c85"},"categories":["Biotech","AI","Healthcare","Drug Discovery","B2B"],"stage":"growth","founded_year":null,"location":"Shanghai / San Francisco / Singapore","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/anew-labs","contact_email":null,"added_at":"2026-09-16T08:10:13.716Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T14:09:14.395Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-16T08:10:13.716Z","updated_at":"2026-09-16T08:10:13.716Z"}},{"listing_type":"company","name":"Nutshell Therapeutics","slug":"nutshell-therapeutics","tagline":"AI-physics allosteric drug discovery for undruggable targets","description":"Nutshell Therapeutics (宇道生物) is a Shanghai-based clinical-stage biotech pioneering AI-powered allosteric drug discovery for proteins that are hard to drug with conventional approaches. Its proprietary AlloStar AI-physics hybrid platform supports a pipeline focused on oncology and expanding into other disease areas. Lead program NTS071, a p53 Y220C allosteric reactivator, is advancing in Phase I/II trials in the U.S. and China. Public company materials list offices in Shanghai and Hong Kong Science Park.","url":"http://allonutshell.com/","is_stealth":false,"normalized_domain":"allonutshell.com","normalized_url_key":"allonutshell.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://mma.prnewswire.com/media/2679072/Nutshell_Therapeutics_Logo.jpg","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/nutshell-therapeutics","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"http://allonutshell.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"http://allonutshell.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"297d623a-9f89-44de-aba6-703614abadfe"},"categories":["Biotech","AI","Healthcare"],"stage":"series-b+","founded_year":null,"location":"Shanghai, China","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/nutshell-therapeutics","contact_email":null,"added_at":"2026-09-20T14:07:54.098Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T14:07:54.098Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-20T14:07:54.098Z","updated_at":"2026-09-20T14:07:54.098Z"}},{"listing_type":"company","name":"Altis Labs","slug":"altis-labs","tagline":"AI endpoints that predict patient outcomes from clinical trial imaging","description":"Altis Labs is a Toronto-based company building AI endpoints for oncology clinical development. Its flagship model, IPRO, generates survival predictions and spatial imaging biomarkers from routinely acquired radiology CT scans so biopharma sponsors can assess treatment effect earlier than conventional imaging endpoints like ORR. The company trains models on a multimodal oncology database linking imaging, molecular, clinical, and outcomes data. In September 2026 Altis announced a US$25 million Series A co-led by OrbiMed and Qiming Venture Partners USA. Founded in 2019 by Felix Baldauf-Lenschen.","url":"https://www.altislabs.com/","is_stealth":false,"normalized_domain":"altislabs.com","normalized_url_key":"altislabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/5fe3a05ae581e5affb99e825/660ef371c678eddbf0795569_AltisLabs_Logo_GlyphOnly_Dark_Square-256px.png","links":[{"label":"X / Twitter","url":"https://x.com/altislabs","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/altis-labs","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.altislabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.altislabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Felix Baldauf-Lenschen","role":"Founder and CEO","person_slug":"felix-baldauf-lenschen-01ksy1ay2gkfl","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"e6c04218-baf4-4e44-ae18-e419622ba15c"},"categories":["AI","Healthcare","Biotech","Clinical Trials"],"stage":"series-a","founded_year":2019,"location":"Toronto, Ontario, Canada","pricing":null,"twitter":"https://x.com/altislabs","github":null,"linkedin":"https://www.linkedin.com/company/altis-labs","contact_email":null,"added_at":"2026-09-20T02:16:26.428Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T02:16:26.428Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"clinical-trials","name":"Clinical Trials","note":null,"profile_url":"/industries/clinical-trials"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-20T02:16:26.428Z","updated_at":"2026-09-20T02:16:26.428Z"}},{"listing_type":"company","name":"Spearhead Bio","slug":"spearhead-bio","tagline":"Plant genome engineering with large DNA cargo via transposable elements","description":"Spearhead Bio is a St. Louis agtech company spun out of the Donald Danforth Plant Science Center. It develops genome-engineering tools that combine CRISPR targeting with transposable-element machinery to insert, replace, copy, rearrange, and stack large DNA sequences in plant genomes for GMO and non-GMO trait programs. Founded by Dr. Keith Slotkin; Mike Bielski is CEO. Public materials describe licensing of its TAHITI platform and a September 2026 seed financing led by BioGenerator Ventures and Danforth Technology Company.","url":"https://spearheadbio.com/","is_stealth":false,"normalized_domain":"spearheadbio.com","normalized_url_key":"spearheadbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://spearheadbio.com/wp-media/DSC09797-1200x630.jpg","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/spearhead-bio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://spearheadbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://spearheadbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"person_slug":"keith-slotkin-0uxf76b5cjvzq","name":"Keith Slotkin","role":"Founder","bio":null,"location":null,"image_url":null,"image_asset_id":null,"links":[]},{"person_slug":"mike-bielski-2kxserhq886h2","name":"Mike Bielski","role":"CEO","bio":null,"location":null,"image_url":null,"image_asset_id":null,"links":[]}],"media":{"logo_asset_id":"c1b29efa-e378-482a-88b2-1522803515f5"},"categories":["Agtech","Biotech","Agriculture","Genome Engineering"],"stage":"seed","founded_year":2024,"location":"St. Louis, MO, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/spearhead-bio","contact_email":null,"added_at":"2026-09-19T17:20:04.256Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-19T17:21:34.496Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"agriculture","name":"Agriculture","note":null,"profile_url":"/industries/agriculture"},{"kind":"industry","slug":"agtech","name":"AgTech","note":null,"profile_url":"/industries/agtech"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"genome-engineering","name":"Genome Engineering","note":null,"profile_url":"/industries/genome-engineering"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-19T17:20:04.256Z","updated_at":"2026-09-19T17:20:04.256Z"}},{"listing_type":"company","name":"Big Picture Bio","slug":"big-picture-bio","tagline":"World models for cancer combination therapies","description":"Big Picture Bio is a UK therapeutics company using generative world models to identify, design, and optimise cancer drug combinations. The platform models how tumours, immune cells, and surrounding tissue interact so teams can prioritise combinations for wet-lab validation. Founded by Deep Science Ventures veterans and based in the UK.","url":"https://bigpicturebio.com/","is_stealth":false,"normalized_domain":"bigpicturebio.com","normalized_url_key":"bigpicturebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bigpicturebio.com/img/favicon-180.png","links":[{"label":"X / Twitter","url":"https://x.com/bigpicturebio","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/big-picture-bio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://bigpicturebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://bigpicturebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Kerstin Papenfuss","role":"CEO and co-founder","person_slug":"kerstin-papenfuss-1dshmb8zovifi","bio":null,"location":null,"links":[]},{"name":"Mark Hammond","role":"CTO and co-founder","person_slug":"mark-hammond-1kif1ipssf4v2","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"415b41d1-52be-45bb-ae8a-51a1e474bbf5"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-18T11:23:35.924Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T11:23:35.924Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T11:23:35.924Z","updated_at":"2026-09-18T11:23:35.924Z"}},{"listing_type":"company","name":"Electra Therapeutics","slug":"electra-therapeutics","tagline":"SIRP-targeted antibody therapies for immune disease and cancer","description":"Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP) for immunological diseases and cancer. Lead programs include ELA026. The company completed an upsized U.S. IPO in September 2026 (Nasdaq: ETRA).","url":"https://electra-therapeutics.com/","is_stealth":false,"normalized_domain":"electra-therapeutics.com","normalized_url_key":"electra-therapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://electra-therapeutics.com/wp-content/uploads/2022/01/Group-6321-300x300.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/electra-tx","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://electra-therapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://electra-therapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"6f24c092-8745-4a75-a981-0ef95cf6d154"},"categories":["Biotech","Healthcare","Immunology","B2B"],"stage":"public","founded_year":null,"location":"South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/electra-tx","contact_email":null,"added_at":"2026-09-18T05:06:51.351Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T05:06:51.351Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"immunology","name":"Immunology","note":null,"profile_url":"/industries/immunology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T05:06:51.351Z","updated_at":"2026-09-18T05:06:51.351Z"}},{"listing_type":"company","name":"RegCell","slug":"regcell","tagline":"Regulatory T-cell therapies to restore immune tolerance in autoimmune disease","description":"RegCell is a biotechnology company developing regulatory T-cell (Treg) therapies for autoimmune diseases and transplantation. Its platform epigenetically reprograms T cells based on discoveries by scientific founder Dr. Shimon Sakaguchi. Headquartered in Emeryville, California, with roots and R&D ties in Japan, RegCell is advancing toward clinical development for autoimmune indications. CEO Michael McCullar, PhD.","url":"https://regcellbio.com/","is_stealth":false,"normalized_domain":"regcellbio.com","normalized_url_key":"regcellbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://regcellbio.com/wp-content/uploads/2025/03/regcell-logo-final.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/regcell","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://regcellbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://regcellbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"7d00f287-357c-46d6-8700-36fc72d4b384"},"categories":["Biotech","Healthcare","Cell Therapy","B2B"],"stage":"series-a","founded_year":null,"location":"Emeryville, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/regcell","contact_email":null,"added_at":"2026-09-18T05:04:34.717Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T05:04:34.717Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T05:04:34.717Z","updated_at":"2026-09-18T05:04:34.717Z"}},{"listing_type":"company","name":"Sling Therapeutics","slug":"sling-therapeutics","tagline":"Developing oral therapies for thyroid eye disease","description":"Sling Therapeutics is a biopharmaceutical company developing treatments for thyroid eye disease. Its lead pipeline program, linsitinib, is in late-stage development as an oral therapy for TED. The company is based in Ann Arbor, Michigan.","url":"https://slingtx.com/","is_stealth":false,"normalized_domain":"slingtx.com","normalized_url_key":"slingtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://slingtx.com/wp-content/uploads/2021/11/cropped-favicon2_1-32x32.png","links":[],"entry_points":[{"kind":"homepage","url":"https://slingtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://slingtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2b0cf862-877d-467f-bded-5f45fde90b03"},"categories":["Biotech","Healthcare","Therapeutics"],"stage":null,"founded_year":null,"location":"Ann Arbor, Michigan","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/sling-tx","contact_email":null,"added_at":"2026-09-18T02:16:28.550Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T02:16:28.550Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T02:16:28.550Z","updated_at":"2026-09-18T02:16:28.550Z"}},{"listing_type":"company","name":"Mithrl","slug":"mithrl","tagline":"Biomedical world model for scientific decision-making in biopharma","description":"Mithrl builds a biomedical AI platform that grounds R&D decisions in validated biology. Its Mithrl-1 platform combines a proprietary biomedical world model with an agentic harness for model routing and orchestration, and is designed to deploy inside customer environments alongside proprietary data. The company says the platform helps teams identify targets and biomarkers, interpret results in biological context, and produce auditable insights. In September 2026 it announced a $20M Series A led by Obvious Ventures, with participation from Headline, AGI House, and pharma executives. Co-founders include CEO Vivek Adarsh and CTO Shara Balakrishnan.","url":"https://www.mithrl.com/","is_stealth":false,"normalized_domain":"mithrl.com","normalized_url_key":"mithrl.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.sanity.io/images/vg07j0q0/production/1cfb562f53dc8a8cbdf6a7e9dea06844204a9313-1200x630.png?w=1200&h=630&fit=max&auto=format","links":[{"label":"X","url":"https://x.com/mithrl_ai","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/mithrl-ai","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.mithrl.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.mithrl.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Vivek Adarsh","role":"Co-Founder & CEO","person_slug":"vivek-adarsh-0ulss458a91t5","bio":null,"location":null,"links":[]},{"name":"Shara Balakrishnan","role":"Co-Founder & CTO","person_slug":"shara-balakrishnan-3c93nookrmxuw","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"ce733a4e-da29-4832-874e-056ad6429606"},"categories":["Biotech","AI","Healthcare","Drug Discovery","Enterprise Software"],"stage":"series-a","founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/mithrl_ai","github":null,"linkedin":"https://www.linkedin.com/company/mithrl-ai","contact_email":null,"added_at":"2026-09-17T17:21:43.885Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-17T17:21:43.885Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"enterprise-software","name":"Enterprise Software","note":null,"profile_url":"/industries/enterprise-software"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-17T17:21:43.885Z","updated_at":"2026-09-17T17:21:43.885Z"}},{"listing_type":"company","name":"Polyphron","slug":"polyphron","tagline":"AI-guided tissue foundry for artificial human biology","description":"Polyphron is a New York biotech building an autonomous tissue foundry that manufactures and simulates donor-diverse human tissues. Its platform combines physical tissue production from stem cells with a simulation layer intended to help test therapeutic hypotheses against living human biology. The company publicly describes products including a Tissue Foundry and Tissue World Model, and announced a $20M seed round led by Quiet Capital (with Gradient, Haystack, and Compound) in September 2026. Founders include CEO Matthew Osman, CSO Fabio Boniolo, and Chief AI Scientist Vinh Q. Tran.","url":"https://www.polyphron.com/","is_stealth":false,"normalized_domain":"polyphron.com","normalized_url_key":"polyphron.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/6aa26324ee6b1b267c6abb67/6aa973048a629ba43946ab25_Group%201538233483%20(2).png","links":[{"label":"X","url":"https://x.com/polyphron","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/polyphron","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.polyphron.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.polyphron.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Matthew Osman","role":"CEO","person_slug":"matthew-osman-0tloed29cudra","bio":null,"location":null,"links":[]},{"name":"Fabio Boniolo","role":"CSO","person_slug":"fabio-boniolo-2k4l3n99lsqzl","bio":null,"location":null,"links":[]},{"name":"Vinh Q. Tran","role":"Chief AI Scientist","person_slug":"vinh-q-tran-2o1cvgloeii6p","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"1372eeda-4bb2-4c51-873c-6e824d554cef"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":"seed","founded_year":null,"location":"New York, NY, USA","pricing":null,"twitter":"https://x.com/polyphron","github":null,"linkedin":"https://www.linkedin.com/company/polyphron","contact_email":null,"added_at":"2026-09-17T17:21:38.118Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-17T17:21:38.118Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-17T17:21:38.118Z","updated_at":"2026-09-17T17:21:38.118Z"}},{"listing_type":"company","name":"Cerentry Bio","slug":"cerentry-bio","tagline":"Brain shuttle for systemic drug delivery across brain barriers","description":"Cerentry Bio is a Denmark-based biotech spin-out developing a proprietary brain shuttle to transport systemically administered therapeutics across the brain's protective barriers. Rather than focusing only on the blood-brain barrier, Cerentry develops drug conjugates for transport across the blood-cerebrospinal fluid barrier (BCSFB) to improve access to the central nervous system. The company is based on collaborative work between professors at the Technical University of Denmark and the University of Copenhagen and participates in the BioInnovation Institute / Lundbeck Foundation Venture Lab program.","url":"https://www.cerentry.com/","is_stealth":false,"normalized_domain":"cerentry.com","normalized_url_key":"cerentry.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://images.squarespace-cdn.com/content/v1/69bbe2d7a07ba25e9ceacc40/1a4b8178-d00b-4e16-bf53-21db5f9d6a63/Logo+Cerentry.png?format=1500w","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/cerentry","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.cerentry.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.cerentry.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Maria Deslauriers","role":"CEO / Co-Founder","person_slug":"maria-deslauriers-34v3dk6xi56vb","bio":null,"location":null,"links":[]},{"name":"Katrine Qvortrup","role":"CSO / Co-Founder","person_slug":"katrine-qvortrup-2wkhvhmxd89ul","bio":null,"location":null,"links":[]},{"name":"Mette Rosenkilde","role":"Co-Founder","person_slug":"mette-rosenkilde-1g3rq8g1v0bb1","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"8e643254-e3cf-466f-92ee-26cc51858f55"},"categories":["Biotech","Healthcare","Drug Delivery","B2B"],"stage":null,"founded_year":null,"location":"Denmark","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/cerentry","contact_email":null,"added_at":"2026-09-16T08:10:36.446Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-16T08:10:36.446Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-delivery","name":"Drug Delivery","note":null,"profile_url":"/industries/drug-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-16T08:10:36.446Z","updated_at":"2026-09-16T08:10:36.446Z"}},{"listing_type":"company","name":"Evvy","slug":"evvy","tagline":"AI precision medicine platform for women's health powered by the vaginal microbiome","description":"Evvy is a women's health company that offers at-home vaginal microbiome testing and clinician-reviewed care pathways spanning vaginal health, fertility, and menopause. Founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy operates a CLIA-certified metagenomic sequencing test and EvvyAI guidance on top of its microbiome dataset. Public site: evvy.com.","url":"https://www.evvy.com/","is_stealth":false,"normalized_domain":"evvy.com","normalized_url_key":"evvy.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/63b49401f4a5bbfcde3e4e23/66c88e0e3c3086aac5a83c4b_Evvy%20Favicon.png","links":[{"label":"X / Twitter","url":"https://twitter.com/evvybio","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/evvybio","platform":"linkedin"},{"label":"Instagram","url":"https://www.instagram.com/evvy/","platform":"instagram"},{"label":"Facebook","url":"https://www.facebook.com/evvybio/","platform":"facebook"}],"entry_points":[{"kind":"homepage","url":"https://www.evvy.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.evvy.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.evvy.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Priyanka Jain","role":"Co-Founder","person_slug":"priyanka-jain-19zyl6wfgi554","bio":null,"location":null,"links":[]},{"name":"Laine Bruzek","role":"Co-Founder","person_slug":"laine-bruzek-21lqzkh8b8j4f","bio":null,"location":null,"links":[]},{"name":"Pita Navarro","role":"Co-Founder","person_slug":"pita-navarro-2zhl9bit9fveg","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"9147e049-978d-4dc6-8b08-39d9e5543d2c"},"categories":["Health","Biotech","AI"],"stage":"series-b+","founded_year":2021,"location":"New York, United States","pricing":null,"twitter":"https://twitter.com/evvybio","github":null,"linkedin":"https://www.linkedin.com/company/evvybio","contact_email":null,"added_at":"2026-09-15T17:16:34.549Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-15T17:16:34.549Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"health","name":"Health","note":null,"profile_url":"/industries/health"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-15T17:16:34.549Z","updated_at":"2026-09-15T17:16:34.549Z"}},{"listing_type":"company","name":"N&E Innovations","slug":"n-e-innovations","tagline":"Plant-based antimicrobial tech from upcycled food waste","description":"N&E Innovations is a Singapore-based biotech company founded in 2020 that develops ViKANG, a natural antimicrobial agent derived from upcycled food waste for coatings, packaging, hospitality, and related use cases. Public materials describe food-safe, plant-based formulations intended as alternatives to harsh chemical disinfectants, with offices in Singapore and South Korea. Founded by Didi Gan.","url":"https://vi-kang.com/","is_stealth":false,"normalized_domain":"vi-kang.com","normalized_url_key":"vi-kang.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://vi-kang.com/wp-content/uploads/sites/16/2024/05/cropped-nei-icon-192x192.png","links":[],"entry_points":[{"kind":"homepage","url":"https://vi-kang.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"contact","url":"https://vi-kang.com/contact/","audience":"any","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://vi-kang.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://vi-kang.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Didi Gan","role":"Founder and Managing Director","person_slug":"didi-gan-1clslhqtlq32w","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"b17bc81d-fd3b-48c5-bcbf-04ce8a3668e5"},"categories":["BioTech","Climate","Food Tech","Sustainability"],"stage":"series-a","founded_year":2020,"location":"Singapore","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-13T08:14:48.696Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-13T08:14:48.696Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate","name":"Climate","note":null,"profile_url":"/industries/climate"},{"kind":"industry","slug":"food-tech","name":"Food Tech","note":null,"profile_url":"/industries/food-tech"},{"kind":"industry","slug":"sustainability","name":"Sustainability","note":null,"profile_url":"/industries/sustainability"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-13T08:14:48.696Z","updated_at":"2026-09-13T08:14:48.696Z"}},{"listing_type":"company","name":"Halmos Labs","slug":"halmos-labs","tagline":"Automated biotech R&D for maximum information per experiment","description":"Halmos Labs is a Lund, Sweden biotech company in Y Combinator Fall 2026. It builds automated biotech R&D focused on validity and interpretability, running research and simulations from wet-lab experiment design to cancer vaccine manufacturing. Founded in 2026 by Mattias Akke (CEO) and Linus von Ekensteen Löfgren (CTO). Its first product is Halmos Bio at https://halmoslabs.com/.","url":"https://halmoslabs.com/","is_stealth":false,"normalized_domain":"halmoslabs.com","normalized_url_key":"halmoslabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://halmoslabs.com/halmos-symbol.png","links":[{"label":"Y Combinator","url":"https://www.ycombinator.com/companies/halmos-labs"}],"entry_points":[{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Mattias Akke","role":"Founder and CEO","person_slug":"mattias-akke-3dl5m9duqb1h9","bio":null,"location":null,"links":[]},{"name":"Linus von Ekensteen Löfgren","role":"Founder and CTO","person_slug":"linus-von-ekensteen-l-fgren-2xn364093azto","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"63b5073c-4d03-4212-a6cd-7e13d92739af"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":"pre-seed","founded_year":2026,"location":"Lund, Sweden","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-12T08:08:19.611Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-12T08:08:19.611Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-12T08:08:19.611Z","updated_at":"2026-09-12T08:08:19.611Z"}},{"listing_type":"company","name":"Navion Neurosciences","slug":"navion-neurosciences","tagline":"Precision sodium-channel medicines for epilepsy and neuropathic pain","description":"Navion Neurosciences is a preclinical biotechnology company developing precision sodium-channel therapeutics for neurological diseases such as genetic epilepsies and chronic neuropathic pain. Its NaViGATion platform combines AI-enabled chemistry, structural biology, and ion-channel expertise. Headquartered at the Commonwealth Bio Accelerator in Charlottesville, Virginia. Public site: navionneuro.com.","url":"https://navionneuro.com/","is_stealth":false,"normalized_domain":"navionneuro.com","normalized_url_key":"navionneuro.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://navionneuro.com/wp-content/themes/navion-wordpress-theme-v5-clean-23/assets/logo-navion.png","links":[],"entry_points":[{"kind":"homepage","url":"https://navionneuro.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://navionneuro.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"person_slug":"andrew-krouse-2qty1fjb9bn4n","name":"Andrew Krouse","role":"Founder, President and CEO","bio":null,"location":null,"image_url":null,"image_asset_id":null,"links":[]}],"media":{"logo_asset_id":"0d0c6724-ea0e-482a-8501-198d2b3d0492"},"categories":["Biotech","Healthtech","AI"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-11T02:11:13.877Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-11T02:13:03.727Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthtech","name":"HealthTech","note":null,"profile_url":"/industries/healthtech"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-11T02:11:13.877Z","updated_at":"2026-09-11T02:11:13.877Z"}},{"listing_type":"company","name":"Identifai Genetics","slug":"identifai-genetics","tagline":"AI-powered non-invasive prenatal genetic testing from maternal blood","description":"Tel Aviv-based company developing AI solutions for non-invasive fetal DNA sequencing and prenatal genetic health analysis from a maternal blood sample, aiming for broader genomic insight earlier in pregnancy.","url":"https://identifai-genetics.com/","is_stealth":false,"normalized_domain":"identifai-genetics.com","normalized_url_key":"identifai-genetics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://identifai-genetics.com/wp-content/uploads/2026/08/Group-3742.png","links":[],"entry_points":[{"kind":"homepage","url":"https://identifai-genetics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://identifai-genetics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8032be08-49c8-48e0-840e-9211e9258bda"},"categories":["Healthtech","AI","Biotech","Diagnostics"],"stage":null,"founded_year":null,"location":"Tel Aviv, Israel","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-10T11:57:32.531Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-10T11:57:32.531Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"healthtech","name":"HealthTech","note":null,"profile_url":"/industries/healthtech"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-10T11:57:32.531Z","updated_at":"2026-09-10T11:57:32.531Z"}},{"listing_type":"company","name":"Solstice Oncology","slug":"solstice-oncology","tagline":"Neoadjuvant immuno-oncology therapies designed to improve cure rates","description":"Solstice Oncology is a Boston clinical-stage immuno-oncology company developing porustobart, an engineered CTLA-4 antibody, in combination with anti–PD-1 therapy for neoadjuvant treatment of early-stage cancers, beginning with MSS stage III colon cancer. Led by CEO Caroline J. Loew. Public site: solsticeoncology.com.","url":"https://www.solsticeoncology.com/","is_stealth":false,"normalized_domain":"solsticeoncology.com","normalized_url_key":"solsticeoncology.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://images.squarespace-cdn.com/content/v1/6a6c9ce51d9c4447456022a0/b1803ba3-9069-49f7-b0f9-1da916cefd56/favicon.ico","links":[{"label":"X / Twitter","url":"https://x.com/SolsticeOnc","platform":"x"}],"entry_points":[{"kind":"homepage","url":"https://www.solsticeoncology.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.solsticeoncology.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Caroline J. Loew","role":"President and CEO","person_slug":"caroline-j-loew-1egiu4nxlbbce","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"14d98e23-24cd-401f-8b2d-d020642e89bd"},"categories":["Biotech","Health","Oncology"],"stage":null,"founded_year":null,"location":"Boston, MA","pricing":null,"twitter":"https://x.com/SolsticeOnc","github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-10T08:20:47.746Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-10T08:20:47.746Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"health","name":"Health","note":null,"profile_url":"/industries/health"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-10T08:20:47.746Z","updated_at":"2026-09-10T08:20:47.746Z"}},{"listing_type":"company","name":"MOA Foodtech","slug":"moa-foodtech","tagline":"AI-directed fermentation turning food byproducts into functional ingredients","description":"MOA Foodtech develops next-generation functional ingredients using AI and fermentation. Its public positioning focuses on transforming food-industry byproducts into sustainable protein and related ingredients. The company publishes from moafoodtech.com.","url":"https://www.moafoodtech.com/","is_stealth":false,"normalized_domain":"moafoodtech.com","normalized_url_key":"moafoodtech.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[],"entry_points":[{"kind":"homepage","url":"https://www.moafoodtech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.moafoodtech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Food Tech","Climate","Biotech","AI"],"stage":null,"founded_year":null,"location":"Spain","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-10T02:26:41.635Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-10T02:26:41.635Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate","name":"Climate","note":null,"profile_url":"/industries/climate"},{"kind":"industry","slug":"food-tech","name":"Food Tech","note":null,"profile_url":"/industries/food-tech"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-10T02:26:41.635Z","updated_at":"2026-09-10T02:26:41.635Z"}},{"listing_type":"company","name":"BrainChild Bio","slug":"brainchild-bio","tagline":"Kids-first clinical-stage biotech developing CAR T therapies for CNS tumors","description":"BrainChild Bio is a clinical-stage biotechnology company developing CAR T cell therapies for tumors in the central nervous system. It prioritizes pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG), with plans to expand its platform to adult CNS indications such as glioblastoma. The company is based in Seattle and Cambridge and spun out of research at Seattle Children’s.","url":"https://brainchildbio.com/","is_stealth":false,"normalized_domain":"brainchildbio.com","normalized_url_key":"brainchildbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://brainchildbio.com/wp-content/uploads/2025/04/cropped-apple-touch-icon@1024x-180x180.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/brainchildbio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://brainchildbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://brainchildbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Steven Brugger","role":"Chief Executive Officer","person_slug":"steven-brugger-1f582la7uxnwh","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"586c7788-035c-419d-b349-87d2bf0bde60"},"categories":["Healthcare","Biotech","Life Sciences"],"stage":"series-a","founded_year":2023,"location":"Seattle, United States","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/brainchildbio","contact_email":null,"added_at":"2026-09-10T02:26:09.089Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-10T02:26:09.089Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-10T02:26:09.089Z","updated_at":"2026-09-10T02:26:09.089Z"}},{"listing_type":"company","name":"Pixeom","slug":"pixeom","tagline":"Chemical vision AI for molecular structure analysis in drug discovery","description":"Pixeom is an Oita University-originated startup developing chemical vision AI that converts three-dimensional molecular structures into representations AI models can learn from, aimed at drug discovery and chemical research. The company publicly announced a seed round led by Lifetime Ventures.","url":"https://pixeom.jp/","is_stealth":false,"normalized_domain":"pixeom.jp","normalized_url_key":"pixeom.jp","parent_slug":null,"parent":null,"type_data":{},"logo":"https://pixeom.jp/wp-content/uploads/2025/07/cropped-pixeom-logo-192x192.png","links":[],"entry_points":[{"kind":"homepage","url":"https://pixeom.jp/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://pixeom.jp/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Shigeru Matsuoka","role":"Representative Director","person_slug":"shigeru-matsuoka-3c35s0oz6jdxh","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"5b3692d0-e02b-4cfb-ada9-eb0c448c2b46"},"categories":["AI","Biotech","Drug Discovery","Deep Tech"],"stage":"seed","founded_year":null,"location":"Oita, Japan","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-09T14:10:33.191Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-09T14:10:33.191Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-09T14:10:33.191Z","updated_at":"2026-09-09T14:10:33.191Z"}},{"listing_type":"company","name":"Transfyr","slug":"transfyr","tagline":"Physical AI observability platform for scientific lab work","description":"Transfyr builds physical AI infrastructure that captures scientific execution in the lab—human actions, environmental context, operational metadata, and instrument results—to improve reproducibility, tech transfer, training, and automation. Headquartered at The Engine in Cambridge, MA, with an in-house wet lab. Operated as Transfyr Bio, Inc. Website: transfyr.ai.","url":"https://www.transfyr.ai/","is_stealth":false,"normalized_domain":"transfyr.ai","normalized_url_key":"transfyr.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.sanity.io/images/gbfpwoho/production/4ad6b230292fa662c2cc2c9da480d906cc36b5fd-2048x2048.png?w=180&h=180&fit=max&auto=format","links":[],"entry_points":[{"kind":"homepage","url":"https://www.transfyr.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.transfyr.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"b88b8aee-01bf-458a-b1fb-8298a3b2a010"},"categories":["AI","BioTech","Robotics","Hardware","B2B"],"stage":"seed","founded_year":null,"location":"Cambridge, MA, USA","pricing":null,"twitter":"https://x.com/transfyrai","github":null,"linkedin":"https://www.linkedin.com/company/transfyrai","contact_email":null,"added_at":"2026-09-08T23:19:10.579Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-09T05:38:35.896Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"hardware","name":"Hardware","note":null,"profile_url":"/industries/hardware"},{"kind":"industry","slug":"robotics","name":"Robotics","note":null,"profile_url":"/industries/robotics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-08T23:19:10.579Z","updated_at":"2026-09-08T23:19:10.579Z"}},{"listing_type":"company","name":"sci2sci","slug":"sci2sci","tagline":"Trusted AI infrastructure that verifies enterprise data for regulated industries","description":"Berlin-based sci2sci builds software that connects fragmented enterprise data and verifies evidence behind data and AI outputs for regulated industries such as biopharma. Founded by Angelina Lesnikova and Valerii Kremnev. Tech.eu (8 Sep 2026) reported a €1.2M pre-seed co-led by Heliad and IBB Ventures, with Robin Capital and Superangels participating. Website: sci2sci.com.","url":"https://www.sci2sci.com/","is_stealth":false,"normalized_domain":"sci2sci.com","normalized_url_key":"sci2sci.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.sci2sci.com/favicon/android-chrome-512x512.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.sci2sci.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.sci2sci.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Angelina Lesnikova","role":"Co-Founder","person_slug":"angelina-lesnikova-1p74487uo476s","bio":null,"location":null,"links":[]},{"name":"Valerii Kremnev","role":"Co-Founder and CTO","person_slug":"valerii-kremnev-2ztys1evbfzf7","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"61c70f88-4728-4e32-b22e-8a9169d0a152"},"categories":["AI","Biotech","Data","Enterprise"],"stage":"pre-seed","founded_year":null,"location":"Berlin, Germany","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/sci2sci","contact_email":null,"added_at":"2026-09-08T08:25:59.036Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-08T08:25:59.036Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"data","name":"Data","note":null,"profile_url":"/industries/data"},{"kind":"industry","slug":"enterprise","name":"Enterprise","note":null,"profile_url":"/industries/enterprise"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-08T08:25:59.036Z","updated_at":"2026-09-08T08:25:59.036Z"}},{"listing_type":"company","name":"Typewriter Therapeutics","slug":"typewriter-therapeutics","tagline":"All-RNA genetic medicines with site-specific, non-viral gene insertion","description":"Typewriter Therapeutics develops genetic medicines using an all-RNA platform that inserts full-length therapeutic genes at a natural safe-harbor site without viral vectors or double-strand breaks. The company, with operations in Cambridge, Massachusetts and Tokyo, is advancing applications including in vivo engineered CAR-T cells and gene insertion to the liver for severe rare disease. Its science builds on foundational R2 retrotransposon research from the University of Tokyo and the University of Rochester. Public site: https://typewritertx.com/","url":"https://typewritertx.com/","is_stealth":false,"normalized_domain":"typewritertx.com","normalized_url_key":"typewritertx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://typewritertx.com/wp-content/uploads/2026/07/cropped-Favicon-2-192x192.png","links":[],"entry_points":[{"kind":"homepage","url":"https://typewritertx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"careers","url":"https://typewritertx.com/","audience":"human","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://typewritertx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://typewritertx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[],"media":{"logo_asset_id":"13923c25-e7de-4e5b-80d6-13eba01b7ac7"},"categories":["BioTech","Healthcare"],"stage":"series-a","founded_year":2022,"location":"Cambridge, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-07T23:13:37.573Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-07T23:15:02.781Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-07T23:13:37.573Z","updated_at":"2026-09-07T23:13:37.573Z"}},{"listing_type":"company","name":"Pharosyn","slug":"pharosyn","tagline":"AI infrastructure for pharma commercial decision-making","description":"Pharosyn is a London company building AI systems for pharmaceutical commercial teams. Its platform supports competitive intelligence, monitoring of clinical and regulatory sources, and custom strategic reports for portfolio strategy, market research, forecasting, and business development. Founders include Cambridge graduates Stephen Cowley and Joshua Hampson.","url":"https://www.pharosyn.ai/","is_stealth":false,"normalized_domain":"pharosyn.ai","normalized_url_key":"pharosyn.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.pharosyn.ai/apple-touch-icon.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.pharosyn.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.pharosyn.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Stephen Cowley","role":"Co-founder","person_slug":"stephen-cowley-2a3kp3fcchgt1","bio":null,"location":null,"links":[]},{"name":"Joshua Hampson","role":"Co-founder","person_slug":"joshua-hampson-3isixke1uzq6d","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"fc55e91c-e84b-4b03-9beb-b37ed4a5d656"},"categories":["AI","Healthcare","Enterprise Software","BioTech"],"stage":"seed","founded_year":2025,"location":"London, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-07T23:09:34.046Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-07T23:09:34.046Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"enterprise-software","name":"Enterprise Software","note":null,"profile_url":"/industries/enterprise-software"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-07T23:09:34.046Z","updated_at":"2026-09-07T23:09:34.046Z"}},{"listing_type":"company","name":"Dimenso","slug":"dimenso","tagline":"Physical AI that captures lab experiments as structured data","description":"Dimenso builds physical AI infrastructure for scientific labs. Through voice and vision (including smart glasses), it captures experimental steps in real time, structures records, and generates insights that sync with ELN/LIMS systems. EU Startups News reported a €600,000 seed round led by Draper B1 with Next Tier Ventures.","url":"https://www.dimenso.ai/","is_stealth":false,"normalized_domain":"dimenso.ai","normalized_url_key":"dimenso.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.google.com/s2/favicons?domain=dimenso.ai&sz=128","links":[],"entry_points":[{"kind":"homepage","url":"https://www.dimenso.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.dimenso.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"afa4fed4-642d-4062-bd7b-f82f815d7abb"},"categories":["AI","Biotech","Developer Tools"],"stage":"seed","founded_year":null,"location":"Valencia, Spain / Cambridge, MA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-07T11:34:17.080Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-07T11:34:17.080Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"developer-tools","name":"Developer Tools","note":null,"profile_url":"/industries/developer-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-07T11:34:17.080Z","updated_at":"2026-09-07T11:34:17.080Z"}},{"listing_type":"company","name":"Senticell","slug":"senticell","tagline":"Liquid biopsy using red cell-bound nucleic acids","description":"Senticell is a Philadelphia biotechnology company developing liquid biopsy diagnostics based on red blood cell (RBC)-bound nucleic acids, aiming to surface disease signals that plasma-based approaches may miss. Built on University of Pennsylvania research with an exclusive license to its foundational RBC platform; initial focus includes oncology and infectious disease programs. Co-founded by Neha Shah (CEO) and Dr. Nilam Mangalmurti. Website: https://www.senticell.bio/.","url":"https://www.senticell.bio/","is_stealth":false,"normalized_domain":"senticell.bio","normalized_url_key":"senticell.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static.wixstatic.com/media/478adf_b0b4f4c7832b4b3490f06d63d89251ac%7Emv2.png/v1/fill/w_192%2Ch_192%2Clg_1%2Cusm_0.66_1.00_0.01/478adf_b0b4f4c7832b4b3490f06d63d89251ac%7Emv2.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.senticell.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.senticell.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Neha Shah","role":"Co-founder and CEO","person_slug":"neha-shah-0cbhtcaesgeja","bio":null,"location":null,"links":[]},{"name":"Nilam Mangalmurti","role":"Co-founder and Chief Scientific Advisor","person_slug":"nilam-mangalmurti-290lv8cnwdd90","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"349991d4-973b-4f11-a13b-84ce22881f27"},"categories":["BioTech","Healthcare","Diagnostics","Health Tech"],"stage":"seed","founded_year":null,"location":"Philadelphia, PA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-07T02:26:17.997Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-07T02:26:17.997Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"health-tech","name":"Health Tech","note":null,"profile_url":"/industries/health-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-07T02:26:17.997Z","updated_at":"2026-09-07T02:26:17.997Z"}},{"listing_type":"company","name":"Science4Beauty","slug":"science4beauty","tagline":"Warsaw biotech building recombinant conotoxin skincare actives","description":"Science4Beauty is a Warsaw biotechnology company that designs, produces, and purifies recombinant proteins and bioactive peptides in its own genetic engineering laboratory for advanced skincare and dermatology. Its flagship Miorelaxant Magic line uses a proprietary conotoxin intended to relax facial muscles and smooth wrinkles as a topical, needle-free approach. The company sells through aesthetic clinics (B2B) and direct-to-consumer ecommerce at science4beauty.net.","url":"https://science4beauty.net/","is_stealth":false,"normalized_domain":"science4beauty.net","normalized_url_key":"science4beauty.net","parent_slug":null,"parent":null,"type_data":{},"logo":"https://science4beauty.net/cdn/shop/files/weblogo.png?v=1706623176","links":[],"entry_points":[{"kind":"homepage","url":"https://science4beauty.net/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://science4beauty.net/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Magdalena Janczewska","role":"Founder","person_slug":"magdalena-janczewska-1ahlbsqpqe4ge","bio":null,"location":null,"links":[]},{"name":"Anna Mazurkiewicz-Pisarek","role":"Founder","person_slug":"anna-mazurkiewicz-pisarek-22b8dfso4p6us","bio":null,"location":null,"links":[]},{"name":"Alina Mazurkiewicz","role":"Founder","person_slug":"alina-mazurkiewicz-378bzmf7rbd3d","bio":null,"location":null,"links":[]},{"name":"Agata Stefanek","role":"Founder","person_slug":"agata-stefanek-1yp72b4v0pl5y","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"25664a0d-bb41-40da-a0b2-7b894df1008d"},"categories":["Biotech","Beauty","Healthcare","Consumer"],"stage":null,"founded_year":null,"location":"Warsaw, Poland","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-06T20:07:55.988Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-06T20:07:55.988Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"beauty","name":"Beauty","note":null,"profile_url":"/industries/beauty"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"consumer","name":"Consumer","note":null,"profile_url":"/industries/consumer"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-06T20:07:55.988Z","updated_at":"2026-09-06T20:07:55.988Z"}},{"listing_type":"company","name":"iPremom","slug":"ipremom","tagline":"Molecular diagnostics for early prediction of pregnancy complications","description":"iPremom is a Valencia (Paterna), Spain molecular diagnostics company focused on predicting pregnancy complications from maternal blood. Its MaiRa platform analyses cell-free RNA signals to assess preeclampsia risk from as early as week 9 of pregnancy and is offered in Spain as a laboratory-developed test under clinician prescription. In September 2026 the company announced a 15 million euro seed round led by Amadeus Capital Partners, with Asabys Partners and APEX Ventures participating, to fund clinical validation and commercial/regulatory expansion.","url":"https://ipremom.com/en/","is_stealth":false,"normalized_domain":"ipremom.com","normalized_url_key":"ipremom.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://ipremom.com/wp-content/uploads/2026/02/logo-impremom-new_1000px-e1771584809769.png","links":[],"entry_points":[{"kind":"homepage","url":"https://ipremom.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"contact","url":"https://ipremom.com/en/","audience":"any","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://ipremom.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://ipremom.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Guillermo Ferrando Huertas","role":"CEO","person_slug":"guillermo-ferrando-huertas-3gy2mo563fe9b","bio":null,"location":null,"links":[]},{"name":"Carlos Simon","role":"Chairman and co-founder","person_slug":"carlos-simon-0dph5plthhfh6","bio":null,"location":null,"links":[]},{"name":"Tamara Garrido","role":"Chief Scientific Officer and co-founder","person_slug":"tamara-garrido-1w2av1659ebru","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"41c03753-ad13-4cfe-9eba-dad88b585208"},"categories":["Healthcare","Biotech","Diagnostics","Women's Health"],"stage":"seed","founded_year":null,"location":"Paterna, Valencia, Spain","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-06T14:07:04.220Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-06T14:07:04.220Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"womens-health","name":"Women's Health","note":null,"profile_url":"/industries/womens-health"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-06T14:07:04.220Z","updated_at":"2026-09-06T14:07:04.220Z"}},{"listing_type":"company","name":"Superluminal Medicines","slug":"superluminal-medicines","tagline":"AI and structural biology for hard GPCR drug targets","description":"Superluminal Medicines is a Boston biotechnology company that combines AI/ML, protein dynamics, and structural biology to discover small-molecule drugs against difficult GPCR targets. Its lead program is a selective, biased MC4R agonist aimed at rare genetic forms of obesity and hypothalamic obesity, with a Phase 1 trial expected to begin by the end of 2026.","url":"https://www.superluminalrx.com/","is_stealth":false,"normalized_domain":"superluminalrx.com","normalized_url_key":"superluminalrx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.superluminalrx.com/wp-content/uploads/Color-Horisontal.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.superluminalrx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.superluminalrx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.superluminalrx.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[],"media":{"logo_asset_id":"dcc07db6-6bdd-4fcb-8e29-f520840bdb48"},"categories":["Healthcare","AI","Biotech"],"stage":"series-b+","founded_year":2022,"location":"Boston, MA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-06T02:05:05.127Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-06T02:05:05.127Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-06T02:05:05.127Z","updated_at":"2026-09-06T02:05:05.127Z"}},{"listing_type":"company","name":"Uluu","slug":"uluu","tagline":"ULUU is developing an ocean material that’s carbon negative, home compostable and able to replace all kinds of plastic.","description":"ULUU is developing an ocean material that’s carbon negative, home compostable and able to replace all kinds of plastic.\n\nUluu is a Startmate portfolio company.","url":"https://www.uluu.com.au/","is_stealth":false,"normalized_domain":"uluu.com.au","normalized_url_key":"uluu.com.au","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/67a04d9737a8868afb7c66b5/68915a84e93f6103ddbd4819_uluu%20logo.webp","links":[{"label":"Startmate portfolio profile","url":"https://www.startmate.com/portfolio-companies/uluu","platform":"startmate"}],"entry_points":[{"kind":"homepage","url":"https://www.uluu.com.au/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.uluu.com.au/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Startmate"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/uluu/","contact_email":null,"added_at":"2026-09-04T12:52:11.307Z","added_via":"web","geo":{"keywords":["Startmate","Biotech"],"canonical_facts":["Startmate portfolio company","Valuation band per Startmate: $10-50m"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-04T12:52:11.307Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"startmate","name":"Startmate","note":null,"profile_url":"/industries/startmate"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-04T12:52:11.307Z","updated_at":"2026-09-04T12:52:11.307Z"}},{"listing_type":"company","name":"NE Tech","slug":"ne-tech","tagline":"Food oil extraction technology that produces additive-free oils 85% cheaper.","description":"Food oil extraction technology that produces additive-free oils 85% cheaper.\n\nFood oil extraction technology that produces additive-free oils 85% cheaper, using significantly less energy and removing the traditional drying process completely.\n\nNE Tech is a Startmate portfolio company (cohort W24).","url":"https://naturalextech.com/","is_stealth":false,"normalized_domain":"naturalextech.com","normalized_url_key":"naturalextech.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/67a04d9737a8868afb7c66b5/688ac23e3d7ba348a7f06b19_ne%20tech.webp","links":[{"label":"Startmate portfolio profile","url":"https://www.startmate.com/portfolio-companies/ne-tech","platform":"startmate"}],"entry_points":[{"kind":"homepage","url":"https://naturalextech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://naturalextech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Startmate"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/naturalextech/","contact_email":null,"added_at":"2026-09-04T12:49:18.385Z","added_via":"web","geo":{"keywords":["Startmate","Biotech"],"canonical_facts":["Startmate portfolio company","Startmate cohort: W24","Valuation band per Startmate: $0-10m"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-04T12:49:18.385Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"startmate","name":"Startmate","note":null,"profile_url":"/industries/startmate"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-04T12:49:18.385Z","updated_at":"2026-09-04T12:49:18.385Z"}},{"listing_type":"company","name":"Gamgee","slug":"gamgee","tagline":"Scalable Personalised Cancer Treatment","description":"​Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved\n\nGamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring\n\n​We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next\n\nGamgee is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://www.gamgee.io/","is_stealth":false,"normalized_domain":"gamgee.io","normalized_url_key":"gamgee.io","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/6f6bf83f60f82f47f1a3b961153608810edebb3b.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gamgee","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.gamgee.io/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.gamgee.io/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Genomics","Oncology","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:33:26.675Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Biotech","Genomics","Oncology","AI"],"one_liner_for_search":"Gamgee — Scalable Personalised Cancer Treatment (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Gamgee Technologies","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:33:26.675Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:33:26.675Z","updated_at":"2026-09-03T08:33:26.675Z"}},{"listing_type":"company","name":"Neuromorphic","slug":"neuromorphic","tagline":"Building robots to automate wetlabs","description":"We are building robots that can work autonomously in existing wet labs. Unlike traditional lab automation, which requires dedicated equipment and fixed workflows, our robot moves between workstations, manipulates existing scientific equipment, transports lab materials, and executes experiments using the same lab infrastructure as a human technician. We make the robots easy to manage through natural interfaces like Slack, email, and phone. Our goal is to make deploying robots in wet labs as easy as onboarding a new employee.\n\nNeuromorphic is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://www.neuromorphic.vision/","is_stealth":false,"normalized_domain":"neuromorphic.vision","normalized_url_key":"neuromorphic.vision","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/470f3b57cd018aad9c127e64e5b952d32a64d435.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/neuromorphic","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.neuromorphic.vision/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.neuromorphic.vision/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Industrials","Manufacturing and Robotics","Hard Tech","Robotics","B2B","Biotech","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:33:03.103Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Hard Tech","Robotics","B2B","Biotech","AI"],"one_liner_for_search":"Neuromorphic — Building robots to automate wetlabs (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Industrials","YC subindustry: Industrials / Manufacturing and Robotics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:33:03.103Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"hard-tech","name":"Hard Tech","note":null,"profile_url":"/industries/hard-tech"},{"kind":"industry","slug":"industrials","name":"Industrials","note":null,"profile_url":"/industries/industrials"},{"kind":"industry","slug":"manufacturing-and-robotics","name":"Manufacturing and Robotics","note":null,"profile_url":"/industries/manufacturing-and-robotics"},{"kind":"industry","slug":"robotics","name":"Robotics","note":null,"profile_url":"/industries/robotics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:33:03.103Z","updated_at":"2026-09-03T08:33:03.103Z"}},{"listing_type":"company","name":"Molagri","slug":"molagri","tagline":"Resistance free pesticides.","description":"Molagri develops safer, more effective pesticides for agriculture.\n\nWe design biopesticides that hit a precise molecular target unique to pest insects, knocking out pests while sparing pollinators, beneficial insects, and the wider ecosystem. By modeling how pests are likely to evolve, we stay a step ahead of resistance, keeping our products effective against the pests of today and tomorrow. The higher efficacy and biobased production will also contribute to emissions reductions in both manufacturing and field use.\n\nOur founders are PhD lab mates from the University of Toronto who have worked together for six years and published in Nature Communications and Nature Microbiology.\n\nMolagri is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://molagri.com/","is_stealth":false,"normalized_domain":"molagri.com","normalized_url_key":"molagri.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/71eba8e2b8b0a262e4c76ef41e5ab46b59552e6d.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/molagri","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://molagri.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://molagri.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Industrials","Agriculture","Synthetic Biology","Biotech","Sustainability","Climate"],"stage":null,"founded_year":null,"location":"Toronto, ON, Canada","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:32:14.494Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Synthetic Biology","Biotech","Sustainability","Climate","Agriculture"],"one_liner_for_search":"Molagri — Resistance free pesticides. (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 4","YC industry: Industrials","YC subindustry: Industrials / Agriculture","Regions (per YC): Canada, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:32:14.494Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"agriculture","name":"Agriculture","note":null,"profile_url":"/industries/agriculture"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate","name":"Climate","note":null,"profile_url":"/industries/climate"},{"kind":"industry","slug":"industrials","name":"Industrials","note":null,"profile_url":"/industries/industrials"},{"kind":"industry","slug":"sustainability","name":"Sustainability","note":null,"profile_url":"/industries/sustainability"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:32:14.494Z","updated_at":"2026-09-03T08:32:14.494Z"}},{"listing_type":"company","name":"Rasyn","slug":"rasyn","tagline":"Making chemicals 100,000x faster","description":"We builds foundational AI models for chemistry. Almost nothing you buy is a single chemical. Products like datacenter coolant, GPU thermal paste, paint, and glue are formulations, which are mixtures of around ten ingredients each, and demand for them has grown quickly because of AI and EVs.\n\nDesigning a new formulation is essentially a search problem, because there are more possible mixtures than anyone could ever test, and none of them can be predicted in advance. As a result, bringing a single formulation to market today takes three to five years of trial and error in a lab.\n\nOur models predict how a mixture will behave far faster than the standard methods used today, which lets us design new formulations in weeks rather than years, at a fraction of the cost. To prove this, we used them to invent three chemicals that never existed before, including a PFAS-free coolant for datacenters, and we have since synthesized and patented all three.\n\nWe are already working with some of the largest manufacturers to design formulations for them, and we are building our own lab to generate the data that will train our next models.\n\nRasyn is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://www.rasyn.ai/","is_stealth":false,"normalized_domain":"rasyn.ai","normalized_url_key":"rasyn.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ffda7ce34aee49cfec95fa8aef9ed1a70e4c3e28.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/rasyn","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.rasyn.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.rasyn.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Artificial Intelligence","Deep Learning","Biotech","Manufacturing"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:32:03.651Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Artificial Intelligence","Deep Learning","Biotech","Manufacturing"],"one_liner_for_search":"Rasyn — Making chemicals 100,000x faster (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:32:03.651Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-learning","name":"Deep Learning","note":null,"profile_url":"/industries/deep-learning"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"manufacturing","name":"Manufacturing","note":null,"profile_url":"/industries/manufacturing"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:32:03.651Z","updated_at":"2026-09-03T08:32:03.651Z"}},{"listing_type":"company","name":"Spectre Intelligence","slug":"spectre-intelligence","tagline":"We are a multi-strategy trading firm that trains AI traders.","description":"Spectre Intelligence is a neotrading firm. We create AI traders instead of hiring human ones. Currently trading semis + bio.\n\nSpectre Intelligence is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://www.spectreintelligence.ai/","is_stealth":false,"normalized_domain":"spectreintelligence.ai","normalized_url_key":"spectreintelligence.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/dd275e68bdab3f73081986be229ec8d9f1423ae5.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/spectre-intelligence","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.spectreintelligence.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.spectreintelligence.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Fintech","Asset Management","Biotech","Investing","Trading","Semiconductors"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:31:37.600Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Biotech","Investing","Trading","Semiconductors"],"one_liner_for_search":"Spectre Intelligence — We are a multi-strategy trading firm that trains AI traders. (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 2","YC industry: Fintech","YC subindustry: Fintech / Asset Management","Former names: Spectre Capital","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:31:37.600Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"asset-management","name":"Asset Management","note":null,"profile_url":"/industries/asset-management"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"fintech","name":"FinTech","note":null,"profile_url":"/industries/fintech"},{"kind":"industry","slug":"investing","name":"Investing","note":null,"profile_url":"/industries/investing"},{"kind":"industry","slug":"semiconductors","name":"Semiconductors","note":null,"profile_url":"/industries/semiconductors"},{"kind":"industry","slug":"trading","name":"Trading","note":null,"profile_url":"/industries/trading"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:31:37.600Z","updated_at":"2026-09-03T08:31:37.600Z"}},{"listing_type":"company","name":"Gutgutgoose","slug":"gutgutgoose","tagline":"We sequence your gut and build the probiotics it’s missing","description":"Most data companies pay for their data. Ours pays for itself.\nCustomers send us a stool sample. We sequence it, build a metabolic model of that gut, and simulate whether each probiotic strain has an open niche it can colonize. We formulate the best candidates, then re-sequence 90 days later to see what actually took hold and what changed. Each cycle gives us the baseline gut, the intervention, and the outcome. At scale, the endgame is models that predict chronic disease years before symptoms.\n\nGutgutgoose is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://gutgutgoose.com/","is_stealth":false,"normalized_domain":"gutgutgoose.com","normalized_url_key":"gutgutgoose.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/3b10bdb631232584efc1a8c09e67b74f8b953437.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gutgutgoose","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://gutgutgoose.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://gutgutgoose.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Consumer","Biotech","Personalization","Health & Wellness"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:30:24.933Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Consumer","Biotech","Personalization","Health & Wellness"],"one_liner_for_search":"Gutgutgoose — We sequence your gut and build the probiotics it’s missing (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:30:24.933Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"consumer","name":"Consumer","note":null,"profile_url":"/industries/consumer"},{"kind":"industry","slug":"health-and-wellness","name":"Health & Wellness","note":null,"profile_url":"/industries/health-and-wellness"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"personalization","name":"Personalization","note":null,"profile_url":"/industries/personalization"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:30:24.933Z","updated_at":"2026-09-03T08:30:24.933Z"}},{"listing_type":"company","name":"Enjamb Labs","slug":"enjamb-labs","tagline":"The AI Workforce for Biopharma","description":"I run Enjamb. We've worked with 130 life science companies, preclinical through phase 3, to deploy AI securely inside the systems they already work in.\n\nPharma runs on decades of closed software like Benchling, Veeva, Medidata, and SAS. None of it has an AI layer or speaks MCP, so agents cannot reach the systems where the work lives.\n\nEnjamb is that layer. Our agents run on top of existing systems and data, with no migration, and they reach the lab systems and internal tools no other AI touches. They learn how a team works, then do the work in Slack, in Teams, and in the systems themselves, across preclinical research, clinical evidence, trial design, statistical programming, and regulatory submissions.\n\nThis is AI tailored for how medicine gets made.\n\nEnjamb Labs is a Y Combinator company (Spring 2026). YC-listed status: Active.","url":"https://www.enjamb.ai/","is_stealth":false,"normalized_domain":"enjamb.ai","normalized_url_key":"enjamb.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b1348d79301216902dfdfa731a133bfa809b1447.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/enjamb-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.enjamb.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.enjamb.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["B2B","Artificial Intelligence","SaaS","Biotech","Automation"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:29:10.875Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Spring 2026","Artificial Intelligence","SaaS","B2B","Biotech","Automation"],"one_liner_for_search":"Enjamb Labs — The AI Workforce for Biopharma (Y Combinator Spring 2026)","canonical_facts":["Y Combinator batch: Spring 2026","YC company status: Active","Team size (per YC directory): 2","YC industry: B2B","YC subindustry: B2B","Former names: Enjamb Labs Inc, Enjamb","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:29:10.875Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"automation","name":"Automation","note":null,"profile_url":"/industries/automation"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"saas","name":"SaaS","note":null,"profile_url":"/industries/saas"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:29:10.875Z","updated_at":"2026-09-03T08:29:10.875Z"}},{"listing_type":"company","name":"Infera","slug":"infera","tagline":"Control lab instruments with natural language.","description":"Describe an experiment in plain English, and Infera turns it into a validated, instrument-ready run across the equipment your lab already uses. Infera handles the protocol logic, vendor-specific scripts, data, inventory, and institutional knowledge in one system. An AI-native compiler for the lab: one system from intent to execution.\n\nInfera is a Y Combinator company (Spring 2026). YC-listed status: Active.","url":"https://www.infera.bio/","is_stealth":false,"normalized_domain":"infera.bio","normalized_url_key":"infera.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e31e68f847b8067b4a5a541fed968e4b0739a6c4.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/infera","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.infera.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.infera.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Industrial Bio","SaaS","B2B","Biotech","Automation","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:26:32.447Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Spring 2026","SaaS","B2B","Biotech","Automation","AI"],"one_liner_for_search":"Infera — Control lab instruments with natural language. (Y Combinator Spring 2026)","canonical_facts":["Y Combinator batch: Spring 2026","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Industrial Bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:26:32.447Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"automation","name":"Automation","note":null,"profile_url":"/industries/automation"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"industrial-bio","name":"Industrial Bio","note":null,"profile_url":"/industries/industrial-bio"},{"kind":"industry","slug":"saas","name":"SaaS","note":null,"profile_url":"/industries/saas"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:26:32.447Z","updated_at":"2026-09-03T08:26:32.447Z"}},{"listing_type":"company","name":"WonderTx","slug":"wondertx","tagline":"Extrapolative AI to unlock First-in-Class drugs","description":"We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery.  This should dramatically increase our probability of success.\n\nThere’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.\n\nWonderTx is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://wondertx.ai/","is_stealth":false,"normalized_domain":"wondertx.ai","normalized_url_key":"wondertx.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/08d90d66366f5066cf3ad5ae02f156dc4bcc8ebe.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/wondertx","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://wondertx.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://wondertx.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Generative AI","Biotech"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:26:18.861Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","AI-powered Drug Discovery","Generative AI","Biotech"],"one_liner_for_search":"WonderTx — Extrapolative AI to unlock First-in-Class drugs (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: A Company in Stealth Mode Incorporated","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:26:18.861Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"generative-ai","name":"Generative AI","note":null,"profile_url":"/industries/generative-ai"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:26:18.861Z","updated_at":"2026-09-03T08:26:18.861Z"}},{"listing_type":"company","name":"Illume Labs","slug":"illume-labs","tagline":"24/7 Personal Health & Longevity Companion","description":"Illume is a 24/7 AI personal health & longevity companion that connects your wearables, blood panels, and genomic data to text you personalized and actionable insights. We pull in your health data and fuse it into one secure model. You get daily text updates on what changed, what it means, and what to do next; conversational health Q&A like \"What should I do to improve my bloodwork?\"; cross-data trend detection that catches patterns individual platforms miss; and a full platform to dig deeper, explore your health data, and text your Illume agent anytime. We're 3 MIT grads & friends, with experience at Windsurf, MIT CSAIL, Eli Lilly, & the Broad Institute.\n\nIllume Labs is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://www.illumelabs.ai/","is_stealth":false,"normalized_domain":"illumelabs.ai","normalized_url_key":"illumelabs.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/72dfae7e6f3aa505626a7c902f014e294cc6ab91.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/illume-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.illumelabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.illumelabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Consumer Health and Wellness","Artificial Intelligence","Generative AI","Health Tech","Biotech","Health & Wellness"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:24:13.798Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Artificial Intelligence","Generative AI","Health Tech","Biotech","Health & Wellness"],"one_liner_for_search":"Illume Labs — 24/7 Personal Health & Longevity Companion (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Consumer Health and Wellness","Former names: Illume","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:24:13.798Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"consumer-health-and-wellness","name":"Consumer Health and Wellness","note":null,"profile_url":"/industries/consumer-health-and-wellness"},{"kind":"industry","slug":"generative-ai","name":"Generative AI","note":null,"profile_url":"/industries/generative-ai"},{"kind":"industry","slug":"health-and-wellness","name":"Health & Wellness","note":null,"profile_url":"/industries/health-and-wellness"},{"kind":"industry","slug":"health-tech","name":"Health Tech","note":null,"profile_url":"/industries/health-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:24:13.798Z","updated_at":"2026-09-03T08:24:13.798Z"}},{"listing_type":"company","name":"10x Science","slug":"10x-science","tagline":"The AI-native platform for next-generation protein characterization.","description":"10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development.\n\nAI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early.\n\nWe have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.\n\n10x Science is a Y Combinator company (Winter 2026). YC-listed status: Active.","url":"https://10xscience.com/","is_stealth":false,"normalized_domain":"10xscience.com","normalized_url_key":"10xscience.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/80a81e39e735a3e350222fa5fd72596c97653b0a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/10x-science","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://10xscience.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://10xscience.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["B2B","SaaS","Biotech","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:19:03.504Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2026","SaaS","B2B","Biotech","AI"],"one_liner_for_search":"10x Science — The AI-native platform for next-generation protein characterization. (Y Combinator Winter 2026)","canonical_facts":["Y Combinator batch: Winter 2026","YC company status: Active","Team size (per YC directory): 5","YC industry: B2B","YC subindustry: B2B","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:19:03.504Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"saas","name":"SaaS","note":null,"profile_url":"/industries/saas"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:19:03.504Z","updated_at":"2026-09-03T08:19:03.504Z"}},{"listing_type":"company","name":"Anto Biosciences","slug":"anto-biosciences","tagline":"A Foundation Model for Microbial Communities.","description":"Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. \n\nFounded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature.\n\nAnto Biosciences is a Y Combinator company (Fall 2025). YC-listed status: Active.","url":"https://anto.bio/","is_stealth":false,"normalized_domain":"anto.bio","normalized_url_key":"anto.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/83f56c369ac0fb5e70438516e774b8603717940a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/anto-biosciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://anto.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://anto.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Artificial Intelligence","Generative AI","Biotech","Genomics","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:16:14.842Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Fall 2025","Artificial Intelligence","Generative AI","Biotech","Genomics","Drug discovery"],"one_liner_for_search":"Anto Biosciences — A Foundation Model for Microbial Communities. (Y Combinator Fall 2025)","canonical_facts":["Y Combinator batch: Fall 2025","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare","Former names: Anto","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:16:14.842Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"generative-ai","name":"Generative AI","note":null,"profile_url":"/industries/generative-ai"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:16:14.842Z","updated_at":"2026-09-03T08:16:14.842Z"}},{"listing_type":"company","name":"Play Health","slug":"play-health","tagline":"Perimenopause Care Platform","description":"Play Health is building a perimenopause care platform to provide women and their providers with the tools they need to relieve symptoms fast. It is led by technical, second-time, YC-backed founders Andrea Mazzocchi, PhD and Ian Miller, with an exit and a unicorn between them.\n\nOver 30 million women in the U.S. are experiencing perimenopause symptoms, spending an estimated $15B+ annually on symptom management.  Despite this most only receive generic solutions and struggle to find effective symptom relief.\n\nWe're bringing evidence-based perimenopause care to women through partnerships with medical practices and employer and health benefits programs. Our platform integrates personalized symptom, medication, and lifestyle data to generate AI-powered insights and  clinical protocols, enabling providers to deliver specialized care.\n\nEvery clinical interaction enriches our longitudinal dataset allowing us to create better outcomes for patients, deeper insights for providers, and expand into women’s health broadly. This also enables us to partner with pharma and biotech companies developing therapeutics and diagnostics for women's health.\n\nPlay Health is a Y Combinator company (Fall 2025). YC-listed status: Active.","url":"http://playhealth.com/","is_stealth":false,"normalized_domain":"playhealth.com","normalized_url_key":"playhealth.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/757bc1cfa9101d42dcc0cd813d53a54fd8552a06.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/play-health","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"http://playhealth.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"http://playhealth.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Biometrics","Biotech","Digital Health","Health & Wellness","Women's Health"],"stage":null,"founded_year":null,"location":"Boulder, CO, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:16:02.781Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Fall 2025","Biometrics","Biotech","Digital Health","Health & Wellness","Women's Health"],"one_liner_for_search":"Play Health — Perimenopause Care Platform (Y Combinator Fall 2025)","canonical_facts":["Y Combinator batch: Fall 2025","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:16:02.781Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biometrics","name":"Biometrics","note":null,"profile_url":"/industries/biometrics"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"digital-health","name":"Digital Health","note":null,"profile_url":"/industries/digital-health"},{"kind":"industry","slug":"health-and-wellness","name":"Health & Wellness","note":null,"profile_url":"/industries/health-and-wellness"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"womens-health","name":"Women's Health","note":null,"profile_url":"/industries/womens-health"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:16:02.781Z","updated_at":"2026-09-03T08:16:02.781Z"}},{"listing_type":"company","name":"Scoop","slug":"scoop","tagline":"Automating regulatory submissions for life sciences","description":"We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.\n\nScoop is a Y Combinator company (Fall 2025). YC-listed status: Active.","url":"https://scooplabs.ai/","is_stealth":false,"normalized_domain":"scooplabs.ai","normalized_url_key":"scooplabs.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/70fc9c8245a9de2b245841faf07e0530dd3f51a1.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/scoop","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://scooplabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://scooplabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["B2B","Artificial Intelligence","Biotech","Compliance","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:14:16.373Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Fall 2025","Artificial Intelligence","B2B","Biotech","Compliance","Biotechnology"],"one_liner_for_search":"Scoop — Automating regulatory submissions for life sciences (Y Combinator Fall 2025)","canonical_facts":["Y Combinator batch: Fall 2025","YC company status: Active","Team size (per YC directory): 2","YC industry: B2B","YC subindustry: B2B","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:14:16.373Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"compliance","name":"Compliance","note":null,"profile_url":"/industries/compliance"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:14:16.373Z","updated_at":"2026-09-03T08:14:16.373Z"}},{"listing_type":"company","name":"Convexia","slug":"convexia","tagline":"The world's first AI-maximalist pharma company","description":"An AI-maximalist pharma platform. We use agents to buy drugs, run clinical trials, and sell for a profit. 10x faster and 20x leaner than incumbents.\n\nSourcing Agent: Mines public/private databases and unstructured global data to surface overlooked preclinical candidates.\nScientific Agent: Runs comp bio models (ESM-3, RFdiffusion, Boltz-2, AlphaFold) to assess safety and efficacy in silico.\nCommercial Agent: Analyzes FDA incentives, pricing dynamics, TAM, competitive landscape, and payer alignment.\nClinical Agent: Runs digital twin simulations, evaluates CRO/CMC risk, and builds trial plans to Phase 1.\nPoS Agent: Evaluates the most critical factors that impact the likelihood of clinical trial success. \n\nBuilt by 2 Stanford CS students who have built 3 startups together before.\n\nConvexia is a Y Combinator company (Summer 2025). YC-listed status: Active.","url":"https://www.convexia.bio/","is_stealth":false,"normalized_domain":"convexia.bio","normalized_url_key":"convexia.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/c68bf871c0fe363c6048343df283d9282ab990f4.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/convexia","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.convexia.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.convexia.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Biotech","Drug Delivery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:12:15.441Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2025","AI-powered Drug Discovery","Biotech","Drug Delivery"],"one_liner_for_search":"Convexia — The world's first AI-maximalist pharma company (Y Combinator Summer 2025)","canonical_facts":["Y Combinator batch: Summer 2025","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:12:15.441Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-delivery","name":"Drug Delivery","note":null,"profile_url":"/industries/drug-delivery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:12:15.441Z","updated_at":"2026-09-03T08:12:15.441Z"}},{"listing_type":"company","name":"Panoptive","slug":"panoptive","tagline":"The continuous oversight engine for clinical trials","description":"We turn unstructured monitoring data - monitoring visit reports, EDC data - into structured deviation, safety, and quality findings for human review. Panoptive generates an audit-ready oversight trail as a natural byproduct. \n\nThe platform aggregates findings and identifies systemic patterns across sites and subjects before they compound, and tracks every finding through decision, follow-up, and resolution.\n\nPanoptive is a Y Combinator company (Summer 2025). YC-listed status: Active.","url":"https://panoptive.com/","is_stealth":false,"normalized_domain":"panoptive.com","normalized_url_key":"panoptive.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e968a9edc53bbf932ccbe0585917fe2029077b90.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/panoptive","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://panoptive.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://panoptive.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["B2B","Biotech","Infrastructure","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:10:03.114Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2025","B2B","Biotech","Infrastructure","AI"],"one_liner_for_search":"Panoptive — The continuous oversight engine for clinical trials (Y Combinator Summer 2025)","canonical_facts":["Y Combinator batch: Summer 2025","YC company status: Active","Team size (per YC directory): 2","YC industry: B2B","YC subindustry: B2B","Former names: AgentHub","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:10:03.114Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"infrastructure","name":"Infrastructure","note":null,"profile_url":"/industries/infrastructure"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:10:03.114Z","updated_at":"2026-09-03T08:10:03.114Z"}},{"listing_type":"company","name":"Bramante","slug":"bramante","tagline":"Life sciences reagents and software","description":"We make reagents and software that are purpose built for AI, automated labs, and personalized medicines.\n\nBramante is a Y Combinator company (Spring 2025). YC-listed status: Active.","url":"https://bramantebio.com/","is_stealth":false,"normalized_domain":"bramantebio.com","normalized_url_key":"bramantebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/d13627b06670d3337bda071d8e7bccb8d6728ffd.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/bramante","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://bramantebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://bramantebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Industrials","Manufacturing and Robotics","Artificial Intelligence","Biotech","Manufacturing"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:06:34.533Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Spring 2025","Artificial Intelligence","Biotech","Manufacturing"],"one_liner_for_search":"Bramante — Life sciences reagents and software (Y Combinator Spring 2025)","canonical_facts":["Y Combinator batch: Spring 2025","YC company status: Active","Team size (per YC directory): 2","YC industry: Industrials","YC subindustry: Industrials / Manufacturing and Robotics","Former names: LabKick Corporation, LabKick, Bramante Biologics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:06:34.533Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"industrials","name":"Industrials","note":null,"profile_url":"/industries/industrials"},{"kind":"industry","slug":"manufacturing","name":"Manufacturing","note":null,"profile_url":"/industries/manufacturing"},{"kind":"industry","slug":"manufacturing-and-robotics","name":"Manufacturing and Robotics","note":null,"profile_url":"/industries/manufacturing-and-robotics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:06:34.533Z","updated_at":"2026-09-03T08:06:34.533Z"}}],"total":170,"limit":50,"offset":0}